Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has earned an average recommendation of “Hold” from the eight brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.26.

Several research firms have weighed in on ANTH. Zacks Investment Research raised Anthera Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $6.00 target price on the stock in a research note on Wednesday, March 8th. Jefferies Group LLC lowered their target price on Anthera Pharmaceuticals from $8.00 to $6.40 and set a “hold” rating on the stock in a research note on Monday, March 6th. Finally, ValuEngine cut Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/06/19/anthera-pharmaceuticals-inc-anth-receives-average-rating-of-hold-from-brokerages-updated-updated.html.

Several large investors have recently made changes to their positions in ANTH. Goldman Sachs Group Inc. raised its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. Sabby Management LLC raised its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. UBS Group AG raised its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Anthera Pharmaceuticals by 16.2% in the first quarter. Geode Capital Management LLC now owns 355,172 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 49,391 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Anthera Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 2,691,639 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 886,910 shares in the last quarter.

Anthera Pharmaceuticals (NASDAQ ANTH) traded down 2.13% during midday trading on Monday, hitting $1.84. 104,057 shares of the company’s stock traded hands. The company’s market capitalization is $18.54 million. Anthera Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $4.00. The company has a 50 day moving average of $1.84 and a 200-day moving average of $1.06.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.47) by $0.56. Equities research analysts predict that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current year.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Stock Ratings for Anthera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.